Powered by

Horizon Discovery's SMARTvector shRNA Technology Deployed in Celyad's Successful IND Filing for Next-Generation CAR-T Cell Therapy, CYAD-02

Jul 08, 2019 - Business Wire

Horizon Discovery Group plc (LSE: HZD) ("Horizon"), a company driving the application of gene editing and gene modulation within the global life science market, today announced that Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, received FDA Acceptance of Investigational New Drug (IND) application for the autologous NKG2D based CAR-T cell therapy CYAD-02 that deploys Horizon's optimized ...